FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~May~~November 2026, 2024

BIOADAPTIVES, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		000-54949		46-2592228
(State or Other Jurisdictionof Incorporation)		(~~CommissionFile~~Commission File Number)		(IRS EmployerIdentification No.)

2620 Regatta Drive, Suite 102

Las Vegas, Nevada 89128

(Address of Principal Executive Office) (Zip Code)

(702) 659-8829

Registrant's telephone number, including area code:

N/A

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01: Other Events.

On November 20, 2024, FINRA approved BioAdaptives Inc.’s Reverse split. The reverse split becomes effective on November 21, 2024.

Item 7.01 Regulation FD Disclosure

~~FINRA~~The ~~requires~~Company aissued ~~letter~~press torelease ~~the~~on ~~shareholders~~November ~~regarding~~25, 2024, announcing the ~~Company~~approval ~~issued~~of a ~~press~~human ~~release~~clinical ontrial ~~October~~for 29its product, ~~2024~~Zeranovia, ~~reporting~~by ~~the~~an ~~impending~~Institutional ~~reverse~~Review ~~split~~Board.

ACopies ~~copy~~ of ~~this~~these press ~~release~~releases isare furnished as ~~Exhibit~~Exhibits 99.1 and 99.1(1) to this Current Report on Form 8-K.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description
99.1		Press Release (11/25/24)

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

November 20, 2024		BioAdaptives, Inc.
		BioAdaptives, Inc.
		/s/ James Keener
November 26, 2024		/s/ James E Keener
		James Keener
		James E Keener CEO
		Director and CEO

Filing Compare · BIOADAPTIVES, INC.